Use of Desmopressin Prior to Graft Kidney Biopsy in Patients with High Risk of Bleeding

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
The goal of this study is to evaluate the efficacy and safety of desmopressin to prevent bleeding after percutaneous renal graft biopsy in patients at high risk of bleeding. Researchers will compare desmopressin (DDAVP) to placebo to see if the drug reduces the risk of bleeding events related to kidney biopsy. Participants will receive intravenous desmopressin medication (100ml) or placebo (100mL of saline solution) before the kidney biopsy.
Epistemonikos ID: 767caaa795f2fffbb181d8f51d3d1c8618c007d8
First added on: Apr 17, 2025